HomeCompareRVXCF vs EPRT

RVXCF vs EPRT: Dividend Comparison 2026

RVXCF yields 2500.00% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RVXCF wins by $80609755877.30M in total portfolio value
10 years
RVXCF
RVXCF
● Live price
2500.00%
Share price
$0.08
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$80609755877.37M
Annual income
$74,729,580,081,858,750.00
Full RVXCF calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — RVXCF vs EPRT

📍 RVXCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRVXCFEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RVXCF + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RVXCF pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RVXCF
Annual income on $10K today (after 15% tax)
$212,500.00/yr
After 10yr DRIP, annual income (after tax)
$63,520,143,069,579,940.00/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, RVXCF beats the other by $63,520,143,069,569,020.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RVXCF + EPRT for your $10,000?

RVXCF: 50%EPRT: 50%
100% EPRT50/50100% RVXCF
Portfolio after 10yr
$40304877938.72M
Annual income
$37,364,790,040,935,800.00/yr
Blended yield
92.71%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

RVXCF
No analyst data
Altman Z
-94.1
Piotroski
1/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RVXCF buys
0
EPRT buys
0
No recent congressional trades found for RVXCF or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRVXCFEPRT
Forward yield2500.00%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$80609755877.37M$63.4K
Annual income after 10y$74,729,580,081,858,750.00$12,840.73
Total dividends collected$80198875900.38M$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: RVXCF vs EPRT ($10,000, DRIP)

YearRVXCF PortfolioRVXCF Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$260,700$250,000.00$11,205$505.18+$249.5KRVXCF
2$6,370,070$6,091,121.50$12,672$682.46+$6.36MRVXCF
3$145,912,632$139,096,656.81$14,490$930.48+$145.90MRVXCF
4$3,133,830,814$2,977,704,297.75$16,786$1,282.69+$3133.81MRVXCF
5$63,122,812,060$59,769,613,088.96$19,753$1,791.56+$63122.79MRVXCF
6$1,192,683,724,131$1,125,142,315,226.76$23,677$2,541.64+$1192683.70MRVXCF
7$21,144,559,711,004$19,868,388,126,183.19$29,008$3,672.99+$21144559.68MRVXCF
8$351,818,906,448,043$329,194,227,557,269.44$36,463$5,425.08+$351818906.41MRVXCF
9$5,495,491,397,671,320$5,119,045,167,771,913.00$47,238$8,221.57+$5495491397.62MRVXCF
10$80,609,755,877,367,070$74,729,580,081,858,750.00$63,385$12,840.73+$80609755877.30MRVXCF

RVXCF vs EPRT: Complete Analysis 2026

RVXCFStock

Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada. The company is headquartered in Calgary, Canada.

Full RVXCF Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this RVXCF vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RVXCF vs SCHDRVXCF vs JEPIRVXCF vs ORVXCF vs KORVXCF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.